Back to Speakers

Dr. Stanley Hong is now Senior Adviser to do global marketing & sales and technical support. He was President & CEO of Celltrion Healthcare until December 2015. He joined Celltrion when it was founded in 2002, and has played an important part in its development and success.

Dr. Hong was President of R&D at Celltrion Inc., where he was responsible for product discovery, biosimilar development, and nonclinical / clinical trials. His team led the successful development of REMSIMA®, the world’s first mAb biosimilar, and gained approval for the product in Korea, Japan, Canada, across the European Union, and US. Dr. Hong was also responsible for other biosimilars’ development including Rituximab and Tratsuzumab biosimilars at Celltrion, and has presented data on biosimilars at national / international medical meetings.

Dr. Hong has 35 years industrial experience in the development of biopharmaceutical products and industrial enzymes.

Dr. Hong studied Enzymology and Biochemical Engineering at Seoul National University in Korea, and received a Ph.D from the same institution in 1990. He spent two years at the University of Wisconsin as a Postdoctoral Fellow in the Department of Bacteriology and the School of Pharmacy. Dr. Hong has published more than 40 papers, and holds more than 120 Korean patents and 20 international patents.